[HTML][HTML] Cancer immunotherapy and the immune response in follicular lymphoma
F Stenner, C Renner - Frontiers in oncology, 2018 - frontiersin.org
Follicular lymphoma (FL) is the most frequent indolent lymphoma in the Western world and
is characterized in almost all cases by the t (14; 18) translocation that results in …
is characterized in almost all cases by the t (14; 18) translocation that results in …
How I manage patients with follicular lymphoma
C Casulo - British Journal of Haematology, 2019 - Wiley Online Library
Recent advances in the treatment of follicular lymphoma (FL) have provided insight into
molecular and biological influences on pathogenesis and prognosis. Additionally, numerous …
molecular and biological influences on pathogenesis and prognosis. Additionally, numerous …
End of induction positron emission tomography complete response (PET‐CR) as a surrogate for progression‐free survival in previously untreated follicular lymphoma
JG Dixon, N Dimier, T Nielsen, J Zheng… - British journal of …, 2022 - Wiley Online Library
Progression‐free survival (PFS) has been the regulatory primary end‐point for recent phase
III trials in first‐line follicular lymphoma (FL), but requires prolonged follow‐up. Complete …
III trials in first‐line follicular lymphoma (FL), but requires prolonged follow‐up. Complete …
[HTML][HTML] Rituximab maintenance versus observation after immunochemotherapy (R-CHOP, R-MCP, and R-FCM) in untreated follicular lymphoma patients: a …
C Hirt, E Hoster, M Unterhalt, M Hänel… - …, 2021 - journals.lww.com
The German study groups, the German Low-Grade Lymphoma Study Group (GLSG) and
Ostdeutsche Studiengruppe Hämatologie und Onkologie (OSHO), initiated in 2007 a double …
Ostdeutsche Studiengruppe Hämatologie und Onkologie (OSHO), initiated in 2007 a double …
[HTML][HTML] Predicting early progression in follicular lymphoma
Follicular lymphoma is the most common indolent lymphoma and is associated with slow
tumor growth, long responses to frontline therapy and—generally—favorable outcomes …
tumor growth, long responses to frontline therapy and—generally—favorable outcomes …
Treatment of histologic transformation
C Casulo - Hematology/Oncology Clinics, 2020 - hemonc.theclinics.com
Follicular lymphoma (FL) represents the most common indolent non-Hodgkin lymphoma
(NHL), affecting approximately 14,000 patients in the United States every year. 1 FL has a …
(NHL), affecting approximately 14,000 patients in the United States every year. 1 FL has a …
[HTML][HTML] Management of relapsed follicular lymphoma
TD Rodgers, PM Barr - Annals of Lymphoma, 2021 - aol.amegroups.org
Follicular lymphoma (FL) is the second most common subtype of non-Hodgkin lymphoma
(NHL). While traditional therapy is not considered curative, most patients experience an …
(NHL). While traditional therapy is not considered curative, most patients experience an …
Where to start? Upfront therapy for follicular lymphoma in 2018
JP Leonard, LJ Nastoupil… - Hematology 2014, the …, 2018 - ashpublications.org
The initial approach to the management of follicular lymphoma (FL) is challenging for
patients and physicians. Most FL patients present with minimal symptoms; given the lack of a …
patients and physicians. Most FL patients present with minimal symptoms; given the lack of a …
A brief rituximab, bendamustine, mitoxantrone (R‐BM) induction followed by rituximab consolidation in elderly patients with advanced follicular lymphoma: a phase II …
Treatment for follicular lymphoma (FL) in the elderly is not well standardized. A phase II,
multicentre, single arm trial was conducted in this setting with a brief chemoimmunotherapy …
multicentre, single arm trial was conducted in this setting with a brief chemoimmunotherapy …
Low absolute lymphocyte count is a poor prognostic factor for untreated advanced follicular lymphoma treated with rituximab plus bendamustine: results of the …
S Rai, H Inoue, H Hanamoto, M Matsuda… - International Journal of …, 2021 - Springer
The aim of this trial is to evaluate the utility of rituximab–bendamustine (R–B) for untreated
advanced follicular lymphoma (FL) showing non-optimal response (nOR) to R-CHOP, and to …
advanced follicular lymphoma (FL) showing non-optimal response (nOR) to R-CHOP, and to …